Pharma sector registers growth of 7.7 per cent in May 2016

The Indian pharma sector has registered a growth of 7.7 per cent in May 2016 according to data by AIOCD-AWACS, the market research arm of the All India Organisation of Chemists and Druggists (AIOCD).

June 13, 2016: The ban on Fixed Dose Combination (FDC) seems to have an impact on the growth of the sector, though the experts feel that the effect will gradually wane off in the times to come. Non FDC category, however registered a better growth of 8.4 per cent in May 2016.  344 FDCs were banned by the Centre on the basis of findings of an expert panel.

Therapy wise, it was observed that anti-diabetic, neurology/CNS and cardiac segments registered a higher growth than the market by 250-700 bps while the gastrointestinal and anti-infective segments had lower growth figures. The report mentioned that Indian companies and MNCs posted growth figures of 7.9 per cent and 7 per cent in May 2016 respectively. Also the National List of Essential Medicines and the Non National List of Essential Medicines grew by 2.6 per cent and 8.6 per cent in May, a welcome sign of previous two months of decline.